KRAS and non-small cell lung carcinoma: Preliminary results for the phase I study presented in 2019 showed a partial response (PR) for sotorasib in 5 of 10 patients with KRAS G12C-mutant NSCLC and 4 patients achieved stable disease (SD) for 90% disease control rate by investigator review.